Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive genomic profiling in solid tumours: Navigating promise, challenges, and pathways to clinical integration.

Cancer treatment reviews·2026
Same author

Upfront Modified FOLFOXIRI Plus Panitumumab for <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials.

European journal of cancer (Oxford, England : 1990)·2025
Same author

The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal Cancer.

JCO precision oncology·2025

Related Experiment Video

Updated: Apr 6, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

First-line chemotherapy for mCRC—a review and evidence-based algorithm.

Chiara Cremolini1, Marta Schirripa1, Carlotta Antoniotti1

  • 1Unit of Medical Oncology 2, Azienda Ospedaliera-Universitaria Pisana, Via Roma 67, 56126 Pisa, Italy.

Nature Reviews. Clinical Oncology
|July 29, 2015
PubMed
Summary

Choosing first-line therapy for metastatic colorectal cancer (mCRC) is crucial for patient outcomes. This review examines recent trials to propose an algorithm for optimal upfront treatment selection.

More Related Videos

Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis
04:22

Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis

Published on: March 3, 2023

1.2K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K

Related Experiment Videos

Last Updated: Apr 6, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K
Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis
04:22

Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis

Published on: March 3, 2023

1.2K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K

Area of Science:

  • Medical Oncology
  • Clinical Trials
  • Gastrointestinal Oncology

Background:

  • First-line therapy significantly impacts outcomes in metastatic colorectal cancer (mCRC).
  • Treatment decisions are complex due to numerous options and evolving molecular subtypes.
  • Optimizing chemotherapy backbones and biologic agents is critical for effective mCRC management.

Purpose of the Study:

  • To review key clinical trials on first-line therapies for mCRC over the past decade.
  • To compare chemotherapy doublets, triplets, and monotherapies with or without targeted agents.
  • To propose a patient-oriented algorithm for selecting upfront mCRC treatment.

Main Methods:

  • Systematic literature review of clinical trials in first-line mCRC treatment.
  • Analysis of studies comparing different chemotherapy regimens and biologic agents.
  • Development of a decision-making algorithm based on reviewed evidence.

Main Results:

  • Multiple first-line treatment strategies exist for mCRC, with varying efficacy.
  • The optimal chemotherapy backbone and integration of targeted therapies remain areas of active research.
  • Evidence supports a personalized approach to first-line mCRC therapy.

Conclusions:

  • A patient-centered algorithm can aid clinicians in selecting optimal first-line therapy for mCRC.
  • Further research is needed to refine treatment strategies based on molecular profiles and patient characteristics.
  • Effective upfront treatment is essential for improving survival and quality of life in mCRC patients.